BioCentury
ARTICLE | Company News

Orphan Synergy Europe-Pharma cancer news

July 16, 2012 7:00 AM UTC

Newco Orphan Synergy Europe-Pharma made its public debut with plans to revive development of a cancer vaccine developed more than a decade ago by co-founder Emile Loria at Epimmune Inc. OSE-Pharma acquired worldwide development rights and European commercialization rights from EU Synergy Epitopes S.A. (Geneva, Switzerland) to EP2101 ( EP-2101), which completed Phase II testing to treat non-small cell lung cancer (NSCLC). Orphan Synergy is preparing to start an international Phase III trial in the indication. The vaccine also completed a Phase I/II trial to treat colorectal cancer. OSE-Pharma said it is in discussions with potential investors to raise €2-€5 million ($2.5-$6.2 million). The vaccine contains nine cytotoxic T lymphocyte epitopes from four tumor-associated antigens (TAA) plus the PADRE universal helper T lymphocyte epitope as an immunostimulant. Details were not disclosed. ...